Annual report of the Australian Meningococcal Surveillance Programme, 2000
DOI:
https://doi.org/10.33321/cdi.2001.25.23Keywords:
surveillance, Neisseria meningitidis, meningococcal disease, antibiotics, penicillenAbstract
The National Neisseria Network has undertaken meningococcal isolate surveillance by means of a collaborative laboratory based initiative since 1994. The phenotype (serogroup, serotype and serosubtype) and antibiotic susceptibility of 388 isolates of Neisseria meningitidis from invasive cases of meningococcal disease were determined in 2000. More than 90 per cent of the invasive isolates were either serogroup B or C. There was however, considerable diversity in the phenotypes circulating in the different States and Territories. Serogroup B strains predominated in all jurisdictions except Victoria and were isolated from sporadic cases of invasive disease. Serogroup B phenotypes were generally disparate although phenotypes B:15:P1.7 and B:4:P1.4 were widely distributed. The latter remained especially prominent in New South Wales. The number and proportion of serogroup C isolates again increased in Victoria compared with previous years. Infections with a novel phenotype that was first noted in 1999, C:2a:P1.4(7), were common in Victoria, especially in adolescents and adults, but rarely seen elsewhere in Australia. Phenotype C:2a:P1.2, was also noted in the preceding year and continued to be seen in Victoria in 2000 but was infrequently encountered in other jurisdictions. Serogroup C infections remained common in New South Wales where phenotype C:2a:P1.5 was regularly isolated. About two thirds of all isolates showed decreased susceptibility to the penicillin group of antibiotics (MIC 0.06 to 0.5 mg/L). All isolates tested were susceptible to third generation cephalosporins and to the prophylactic agents rifampicin and ciprofloxacin. Data relating to 147 laboratory-confirmed but culture-negative cases, supplemented information on culture-confirmed cases in this report. Some differences in the patterns of disease were revealed when culture-based and non-culture-based data were compared. Commun Dis Intell 2001;25:113-121.
Downloads
References
Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic micro-organisms. Proc Natl Acad Sci USA 1998;95:3140-3145.
Munro R, Tapsall J. Meningococcal disease in Australia. Commun Dis Intell 1996;20:368-371.
National Neisseria Network. Meningococcal isolate surveillance Australia 1994. Commun Dis Intell 1995:19:286-289.
National Neisseria Network. Meningococcal isolate surveillance Australia 1995. Commun Dis Intell 1996;20:422-424.
The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme 1996. Commun Dis Intell 1997;21:217-221.
Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme. Commun Dis Intell 1998;22:205-211.
The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 1998. Commun Dis Intell 1999;23:317-323.
Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 1999. Commun Dis Intell 2000;24:181-189.
Australian Gonococcal Surveillance Programme. Penicillin sensitivity of gonococci in Australia: development of an Australian gonococcal surveillance programme. Br J Vener Dis 1984;60:226-230.
Porritt RJ, Mercer JL, Munro R. Detection and serogroup determination of Neisseria meningitidis in CSF by polymerase chain reaction (PCR). Pathology 2000;32:42-45.
Robertson PW, Reinbott P, Duffy Y, Binotto E, Tapsall JW. Confirmation of invasive meningococcal disease by single point estimation of IgM antibody to outer membrane protein of Neisseria meningitidis. Pathology 2001:33 (in press).
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2001 Communicable Diseases Intelligence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
